News >

Gilead Acquires Kite Pharma in $11.9 Billion Deal

Silas Inman @silasinman
Published: Monday, Aug 28, 2017

Arie Belldegrun, MD

Arie Belldegrun, MD
Gilead has announced plans to acquire Kite Pharma, which is the developer of the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel; KTE-C19), for 0.00 per share in cash, totaling approximately .9 billion. The decision was unanimously approved by both companies and is expected to complete later this year.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
2nd Annual Live Medical Crossfire®: Hematologic Malignancies OnlineSep 28, 20198.0
Publication Bottom Border
Border Publication